Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Float Percentage Of Total Shares Outstanding : 93.64% (As of Apr. 26, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zynerba Pharmaceuticals's float shares is 50.51 Mil. Zynerba Pharmaceuticals's total shares outstanding is 53.94 Mil. Zynerba Pharmaceuticals's float percentage of total shares outstanding is 93.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zynerba Pharmaceuticals's Insider Ownership is 8.19%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zynerba Pharmaceuticals's Institutional Ownership is 10.70%.

Zynerba Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Zynerba Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	50.51	/	53.94
	=	93.64%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333

Website

http://www.zynerba.com

Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Executives

Kenneth T Jones	officer: See Remarks	C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger	officer: VP, Commercial & Business Dev.	C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree	officer: President	ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher	officer: Chief Financial Officer	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido	director, officer: Chairman & Chief Exec. Officer	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch	director	68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper	director	NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson	director	C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner	director	2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici	director	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker	officer: Chief Legal Officer	C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon	officer: Sec, General Counsel & VP HR	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp	10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison	director